JP2018193401A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018193401A5 JP2018193401A5 JP2018168220A JP2018168220A JP2018193401A5 JP 2018193401 A5 JP2018193401 A5 JP 2018193401A5 JP 2018168220 A JP2018168220 A JP 2018168220A JP 2018168220 A JP2018168220 A JP 2018168220A JP 2018193401 A5 JP2018193401 A5 JP 2018193401A5
- Authority
- JP
- Japan
- Prior art keywords
- solid pharmaceutical
- pharmaceutical formulation
- minutes
- formulation according
- hcmv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007787 solid Substances 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 9
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 241000701022 Cytomegalovirus Species 0.000 claims 4
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 239000007853 buffer solution Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- FWYSMLBETOMXAG-QHCPKHFHSA-N letermovir Chemical compound COC1=CC=CC(N2CCN(CC2)C=2N([C@@H](CC(O)=O)C3=CC=CC(F)=C3N=2)C=2C(=CC=C(C=2)C(F)(F)F)OC)=C1 FWYSMLBETOMXAG-QHCPKHFHSA-N 0.000 claims 2
- 229950010668 letermovir Drugs 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 229940069328 povidone Drugs 0.000 claims 2
- 238000004007 reversed phase HPLC Methods 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010061309 Neoplasm progression Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003480 eluent Substances 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 238000007415 particle size distribution analysis Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000005751 tumor progression Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000003643 water by type Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13003120 | 2013-06-19 | ||
| EP13003120.6 | 2013-06-19 | ||
| EP14165027 | 2014-04-16 | ||
| EP14165027.5 | 2014-04-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016520499A Division JP6445546B2 (ja) | 2013-06-19 | 2014-06-19 | 非晶質レテルモビル及び経口投与のためのその固形医薬製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018193401A JP2018193401A (ja) | 2018-12-06 |
| JP2018193401A5 true JP2018193401A5 (cg-RX-API-DMAC7.html) | 2019-06-20 |
| JP6770035B2 JP6770035B2 (ja) | 2020-10-14 |
Family
ID=50982905
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016520499A Active JP6445546B2 (ja) | 2013-06-19 | 2014-06-19 | 非晶質レテルモビル及び経口投与のためのその固形医薬製剤 |
| JP2018168220A Active JP6770035B2 (ja) | 2013-06-19 | 2018-09-07 | 非晶質レテルモビル及び経口投与のためのその固形医薬製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016520499A Active JP6445546B2 (ja) | 2013-06-19 | 2014-06-19 | 非晶質レテルモビル及び経口投与のためのその固形医薬製剤 |
Country Status (34)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10319612A1 (de) | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| DE102012101673A1 (de) | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
| KR101953270B1 (ko) * | 2013-06-19 | 2019-02-28 | 아이쿠리스 안티-인펙티브 큐어스 게엠베하 | 무정형 레터모비어 및 그의 경구 투여용 고체 제약 제제 |
| CA3019508A1 (en) | 2016-03-31 | 2017-10-05 | Intercept Pharmaceuticals, Inc. | Oral preparation having exceptional elutability |
| US20220152028A1 (en) * | 2019-03-12 | 2022-05-19 | Microbiotix, Inc. | Combination drug treatment for human cytomegalovirus |
| CN111024861A (zh) * | 2019-12-31 | 2020-04-17 | 山东省药学科学院 | 一种莱特莫韦及含莱特莫韦的制剂中有关物质的检测方法 |
| EP3906929A1 (en) | 2020-05-08 | 2021-11-10 | AiCuris GmbH & Co. KG | Letermovir for use in the prevention and the treatment of coronavirus infections |
| WO2022038457A1 (en) | 2020-08-17 | 2022-02-24 | Lupin Limited | A precipitation process for amorphous letermovir |
| WO2022132676A1 (en) * | 2020-12-16 | 2022-06-23 | Merck Sharp & Dohme Corp. | Mini-tablet dosage form of a viral terminase inhibitor and uses thereof |
| CN115403528B (zh) * | 2021-05-27 | 2025-01-07 | 南京正大天晴制药有限公司 | 无定形3,4-二氢喹唑啉衍生物的制备方法 |
| CN114942278B (zh) * | 2022-04-12 | 2023-09-08 | 山东诚创蓝海医药科技有限公司 | 来特莫韦中间体二d-(+)-二对甲基苯甲酰酒石酸乙酸乙酯络合物有关物质的分析方法 |
| WO2024037485A1 (zh) * | 2022-08-15 | 2024-02-22 | 上海迪赛诺化学制药有限公司 | 一种来特莫韦无定形的制备方法 |
| CN116338119A (zh) * | 2023-02-24 | 2023-06-27 | 重庆希韦医药科技有限公司 | 一种来特莫韦包合物溶液体外释放度的测定方法 |
| TW202535393A (zh) | 2023-12-21 | 2025-09-16 | 德商Ａｉｃ246股份兩合公司 | 2-[(4r,s)-8-氟-2-[4-(3-甲氧基苯基)哌嗪-1-基]-3-[2-甲氧基-5-(三氟甲基)苯基]-3,4-二氫喹唑啉-4-基]乙酸之非鏡像異構物胺基醇鹽及胺基醚鹽及其於鏡像異構物分離之用途 |
| WO2025216283A1 (ja) * | 2024-04-12 | 2025-10-16 | 東和薬品株式会社 | レテルモビル含有医薬組成物ならびにその製造方法および用途 |
| CN119745803A (zh) * | 2024-12-30 | 2025-04-04 | 上海奥科达医药科技股份有限公司 | 一种来特莫韦制剂组合物及其制备方法 |
| CN120927867A (zh) * | 2025-10-11 | 2025-11-11 | 成都诺和晟欣生物医药有限公司 | 一种来特莫韦注射液中对映异构体的hplc检测方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10207026A1 (de) * | 2002-02-20 | 2003-08-28 | Boehringer Ingelheim Kg | Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung |
| DE10319612A1 (de) * | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| DE10305785A1 (de) * | 2003-02-12 | 2004-08-26 | Bayer Healthcare Ag | Dihydrochinazoline |
| DE10338402A1 (de) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum |
| CN101198314A (zh) * | 2005-04-12 | 2008-06-11 | 伊兰制药国际有限公司 | 纳米微粒喹唑啉衍生物制剂 |
| DE102005027517A1 (de) * | 2005-06-15 | 2006-12-21 | Bayer Healthcare Ag | Verfahren zur Herstellung von Dihydrochinazolinen |
| WO2012151271A1 (en) * | 2011-05-04 | 2012-11-08 | Merck Sharp & Dohme Corp. | Processes for preparing inhibitors of the hepatitis c virus |
| DE102012101673A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
| DE102012101680A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat |
| DE102012101659A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
| WO2014047562A2 (en) * | 2012-09-21 | 2014-03-27 | Epiphany Biosciences | Method of treating and/or preventing shingles and method of treating and/or preventing zoster associated pain |
| KR101953270B1 (ko) * | 2013-06-19 | 2019-02-28 | 아이쿠리스 안티-인펙티브 큐어스 게엠베하 | 무정형 레터모비어 및 그의 경구 투여용 고체 제약 제제 |
-
2014
- 2014-06-19 KR KR1020167001010A patent/KR101953270B1/ko active Active
- 2014-06-19 MD MDA20150126A patent/MD4673C1/ro active IP Right Grant
- 2014-06-19 PL PL14732545T patent/PL3010891T3/pl unknown
- 2014-06-19 US US14/899,178 patent/US10442773B2/en active Active
- 2014-06-19 PE PE2015002639A patent/PE20160659A1/es unknown
- 2014-06-19 WO PCT/EP2014/062974 patent/WO2014202737A1/en not_active Ceased
- 2014-06-19 CA CA2916143A patent/CA2916143C/en active Active
- 2014-06-19 JP JP2016520499A patent/JP6445546B2/ja active Active
- 2014-06-19 UA UAA201600339A patent/UA117755C2/uk unknown
- 2014-06-19 HR HRP20190936TT patent/HRP20190936T1/hr unknown
- 2014-06-19 AU AU2014283231A patent/AU2014283231B2/en active Active
- 2014-06-19 SG SG11201510426PA patent/SG11201510426PA/en unknown
- 2014-06-19 SM SM20190327T patent/SMT201900327T1/it unknown
- 2014-06-19 ES ES14732545T patent/ES2730958T3/es active Active
- 2014-06-19 HU HUE14732545A patent/HUE043721T2/hu unknown
- 2014-06-19 NZ NZ715387A patent/NZ715387A/en unknown
- 2014-06-19 MX MX2015017758A patent/MX373764B/es active IP Right Grant
- 2014-06-19 CN CN201480040969.XA patent/CN105555771B/zh active Active
- 2014-06-19 EP EP14732545.0A patent/EP3010891B1/en active Active
- 2014-06-19 CN CN202510264255.7A patent/CN120097924A/zh active Pending
- 2014-06-19 CU CU2015000179A patent/CU24619B1/es unknown
- 2014-06-19 PT PT14732545T patent/PT3010891T/pt unknown
- 2014-06-19 RS RS20190686A patent/RS58882B1/sr unknown
- 2014-06-19 DK DK14732545.0T patent/DK3010891T3/da active
- 2014-06-19 ME MEP-2019-149A patent/ME03483B/me unknown
- 2014-06-19 EA EA201600024A patent/EA036131B1/ru unknown
- 2014-06-19 MY MYPI2015002983A patent/MY179502A/en unknown
- 2014-06-19 SI SI201431243T patent/SI3010891T1/sl unknown
- 2014-06-19 BR BR112015031979-3A patent/BR112015031979B1/pt active IP Right Grant
- 2014-06-19 LT LTEP14732545.0T patent/LT3010891T/lt unknown
-
2015
- 2015-12-18 DO DO2015000303A patent/DOP2015000303A/es unknown
- 2015-12-18 PH PH12015502821A patent/PH12015502821B1/en unknown
- 2015-12-18 ZA ZA2015/09239A patent/ZA201509239B/en unknown
- 2015-12-20 IL IL243228A patent/IL243228B/en active IP Right Grant
-
2018
- 2018-09-07 JP JP2018168220A patent/JP6770035B2/ja active Active
- 2018-12-26 IL IL263978A patent/IL263978B/en active IP Right Grant
-
2019
- 2019-06-11 CY CY20191100607T patent/CY1121732T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018193401A5 (cg-RX-API-DMAC7.html) | ||
| ES2389358T3 (es) | Composiciones farmacéuticas de rifaximina | |
| CA2778981C (en) | Solid dispersion of rifaximin | |
| TWI706793B (zh) | 包含紫杉烷之非晶形固體分散體、包含其之錠劑及其等之製備方法 | |
| WO2001095912A1 (fr) | Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph | |
| JP2011500552A (ja) | 胃腸障害を処置するための医薬用組み合わせおよび組成物 | |
| WO2010023690A2 (en) | Prolonged release formulation of amisulpride | |
| Aslam et al. | Techniques and polymers used to design Gastroretentive drug delivery systems–a review | |
| WO2017093444A1 (en) | Compositions for oral administration in the treatment of inflammatory bowel disease | |
| WO2017084486A1 (zh) | 简易制备结肠炎和克罗恩病用高载药量缓释制剂的方法 | |
| Sanghavi et al. | Gastroretentive drug delivery system: An overview | |
| EP3200772A1 (en) | Pharmaceutical compositions comprising alpelisib | |
| EP3797772B1 (en) | Rebamipide for use in prevention and treatment of crohn's disease | |
| DK2996693T3 (en) | USE OF THIAZOLPYRIMIDINON FOR TREATMENT OF INFLAMMATORY GAS | |
| JP6739275B2 (ja) | ゲフィチニブを有効成分とする医薬組成物 | |
| JP2008081448A (ja) | 酒石酸ゾルピデムの苦味マスキング速放性粒子 | |
| JP2005060310A (ja) | 不快な味をマスキングする経口投与用製剤 | |
| PT2123277E (pt) | Agente preventivo ou terapêutico para doenças inflamatórias do intestino | |
| ES2731598T3 (es) | Formulación pediátrica que comprende ácido biliar | |
| WO2007069358A1 (ja) | 新規胃内滞留製剤 | |
| JP2018044017A (ja) | 粒子製剤 | |
| Mandal et al. | Gastro-retentive drug delivery systems and their in vivo success: A | |
| TR201615312A1 (tr) | Antiviral Farmasötik Terkipler | |
| NZ714098B2 (en) | Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease | |
| JP2012250926A (ja) | 粒子製剤 |